secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-07-23T20:34:53+00:00
Accession:  0001193125-26-314214
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics enters $380M at-the-market equity distribution agreement with J.P. Morgan
--------------------------------------------------------------------------------

- Up to $380M of common stock may be sold through J.P. Morgan as sales agent.
- Sales agent commission up to 3.0% of gross sales price per share sold.
- Company not obligated to sell any shares; may suspend solicitations at any time.
- Sales may be made at market prices on Nasdaq or in block transactions.
- Prospectus supplement filed July 23, 2026; shares offered under existing S-3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000119312526314214/0001193125-26-314214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000119312526314214/d143170d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-314214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer